The potent effects observed on BCL2 and MYCN expression in our study highlight the potential therapeutic value of BET inhibitors in other solid tumors driven by high expression of these oncogenes, including small cell lung cancer, medulloblastoma, retinoblastoma, and rhabdomyosarcoma [22,46]. Here, MYCN is linked to rhabdomyosarcoma.